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Since many years, a substantial amount of money from companies and private investors 
is going to research. Hence, valorisation of research supported by this money is gradually 
becoming mandatory from a socio-economical perspective. These groups expect a direct 
impact of this research or for it to be translated into value for their organisation. However, 
it is important to remain vigilant that research remains question-driven and not answer-
driven. Thus, involvement of external parties providing funding should not influence the 
experimental results obtained and reported. Question-driven research might be valoris-
able but needs to a priory expand scientific knowledge. Being part of a knowledge-based 
economy, it should be possible, however, that external parties benefit from research. 
Although expanding scientific knowledge does not have a direct effect on society, its rel-
evance in the scope of fact-based decision making can be of great value. Additionally, this 
knowledge is essential to remain a leader in innovation.
The key objective of this thesis was to gain further insights in the role of vascular smooth 
muscle cells (VSMC) in the development of both intimal and medial vascular calcification 
to find potential targets for holding or regressing vascular disease. Vascular calcification 
is gradually acknowledged as an important risk factor for developing cardiovascular dis-
ease. Cardiovascular disease is still the leading cause of death in the western world and 
has a vast impact on the financial cost of health care systems. Hence, the importance of 
cardiovascular research cannot be overestimated. The impact of cardiovascular disease is 
discussed into greater detail in chapters 1 and 2.
Chapter 3 investigates effects of smoking on development of microcalcification in 
atherosclerotic plaques. Smoking is one of the leading preventable causes of death world-
wide, and quitting smoking is associated with a significant reduction in risk of developing 
cardiovascular disease. Our research identified nicotine as a major component of cigarettes 
increasing microcalcification of atherosclerotic plaques in smokers. Nicotine is well known 
to the general public as the addictive component of cigarettes making the process of 
smoking cessation a long and difficult one. Many different strategies for smoking cessation 
can be employed. As nicotine is the addictive component, a specific group of medications 
known as nicotine replacement therapy has been successfully used to assist people with 
smoking cessation. Although smoking cessation through nicotine replacement therapy 
impacts overall cardiovascular morbidity and mortality caused by smoking, our research 
presents a critical side note to reconsider nicotine replacement therapy. As microcalcifi-
cations greatly reduce plaque stability, the use of nicotine replacement therapy will still 
maintain nicotine blood levels. Hence, the development of microcalcification in plaques 
will not be reduced. This also indicates that reduction in cardiovascular morbidity may 
be less than what could be achieved. Thus, our research promotes the use of alternative 
smoking cessation therapies over nicotine replacement therapy.
Chapter 4 and chapter 5 elaborate on the role of Ucma, a recently discovered 
extra-hepatic vitamin K-dependent protein. Our research demonstrated that this protein 
is present in (calcified) cardiovascular tissue similar to MGP, another extra-hepatic vitamin 
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K-dependent protein involved in the inhibition of ectopic calcification. Previously, it was 
shown that a specific form of MGP (desphosporylated and uncarboxylated MGP) serves as 
a biomarker for vascular vitamin K status and predicts vascular calcification in patients. 
The antibodies against MGP and the use of dp-ucMGP as a biomarker was patented and 
an ELISA was developed to measure circulating MGP levels. This patent and ELISA were 
developed within VitaK BV, a Maastricht University spin off. The patents and assay have 
recently been sold to IDS, an UK based company that markets biomarkers for cardiovas-
cular disease. Also for Ucma, its use as a biomarker for cardiovascular disease has been 
patented. Based on this patent, a new company called GenoGla has been founded. These 
companies offer jobs and hence present themselves as a return-on-investment to society. 
In chapter 5 we have unravelled the role of Ucma in the development of vascular calcifica-
tion and highlighted the BMP-2-pSmad1/5/8-β-catenin dependent-pathway as a potential 
mechanism through which Ucma has a protective effect. Although additional research is 
still required to turn this pathway into a potential diagnostic or therapeutic target. In the 
future this knowledge will be of importance to develop therapies for vascular calcification.
Finally, in chapter 6 we focussed on the role of medial VSMC in the development of 
atherosclerotic plaques. Our results demonstrated that reduced medial VSMC in the vessel 
wall result in significantly larger, more vulnerable atherosclerotic plaques. This finding 
might have great clinical implications. Stents are often coated with anti-proliferative 
drugs to prevent restenosis. Our finding highlights the need to reconsider the coating of 
stents with agents inhibiting VSMC proliferation. Although there are short term benefits 
of this approach, the long term benefits remain questionable and may lead to acceler-
ated atherosclerotic plaque formation in the affected area and hence translate to a larger 
atherosclerotic burden.
